TORONTO, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to announce that it has filed a patent to claim the invention of a small, low-cost device that attaches or is encased in any hand-held probe or ultrasound transducer. The invention also includes a method to use the device to track the probe’s position in 3-dimensional space, as well as its orientation.
“This development will enable us to significantly reduce the cost of our future VMS-PLUS™ equipment and improve its ease of use,” stated Dr. George Adams, CEO of Ventripoint. “The invention can also be used in other applications where accurate real-time positioning information is required, such as robotics.”
The invention is designed to better tolerate patient movement during scanning. In addition, it has the potential to service a larger population of patients, such as people with implanted pacemakers or defibrillators, who are currently not able to have MRI procedures. Each year, approximately 1.5M such cardiac devices are implanted in patients, who could benefit from this new approach.
The Company has built a prototype device and verified its accuracy. It is now doing further design and testing to rapidly bring the technology to commercial readiness. The new approach employs a disposable component, which will be an additional revenue stream for the Company.
About Ventripoint Diagnostics Ltd.
Ventripoint has created tools to monitor patients with heart disease, a leading cause of death in developed countries. VMS is the first cost-effective and accurate tool for measuring heart function. The Company has developed a suite of applications for all major heart diseases and imaging modalities, including congenital heart disease, left or right heart failure and normal hearts.
For further information please contact:
Dr. George Adams, President & CEO,
Telephone: (519) 803-6937
email: gadams@ventripoint.ca
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.